Mentixa (Memantine Hydrochloride)

Mentixa is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease and related cognitive decline.

• Moderate Alzheimer’s disease: helps maintain cognition and daily functioning.
• Severe Alzheimer’s disease: reduces progression of functional decline.
• Alzheimer’s disease combined therapy: used together with cholinesterase inhibitors to enhance symptomatic benefit.

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor, binding to the receptor-associated ion channel with moderate affinity. By blocking excessive calcium influx caused by overstimulation of glutamate, it reduces excitotoxic neuronal injury while preserving normal synaptic transmission, thereby providing symptomatic improvement in neurodegenerative conditions.

Adverse reactions to Memantine may vary in frequency and severity.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Insomnia: difficulty falling or staying asleep, may improve with dose timing adjustments.

Serious or Rare Side Effects

• Seizures: new‑onset convulsions requiring immediate medical attention.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes or jaundice, monitor liver function tests.

When prescribing Memantine, clinicians should consider several safety factors.

• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• History of seizures: monitor closely for increased seizure activity.
• Concurrent NMDA antagonists: avoid co‑administration to reduce additive CNS effects.
• Pregnancy: risk category unknown; use only if potential benefit justifies potential risk.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, necessitating careful management.

Major Interactions (Avoid)

• Amantadine: additive central nervous system effects may increase confusion.
• Ketamine: combined NMDA blockade can lead to excessive sedation or neurotoxicity.
• High‑dose NSAIDs: may raise the risk of peripheral edema.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors: may diminish therapeutic benefit of Memantine.
• Diuretics: can affect blood pressure and electrolyte balance.
• Alcohol: may intensify dizziness and sedation.